Accelerating life science tools R&D with venture studios
Interest in life science technologies and tools is accelerating with the advent of CRISPR and other aspects of synthetic biology. The ability to have a capital efficient way to advance these innovations is very attractive and will help drive innovation.
Four core principles for biotech board meetings
There are many ways to conduct an efficient board meeting, and every management team and board member has different preferences. But here are four key principles I believe will improve everyone’s experience.
How to assassinate your start-up: a legal guide
To be sure, none of these can ensure death with dignity, but most will speed your start-up’s demise – especially when taken as combination therapy.
Venture capital evolved to venture creation. Will it stay that way?
The so-called venture creation model has fully taken root, underpinned and enabled by biotech's longest-ever boom cycle and unprecedented sums of available capital.
Venture partnering
Adam Rosenberg lifts the curtain on what biotech venture partners and entrepreneurs-in-residence really do.
Welcome to RApport
We’re glad you’re here. Read more about the genesis of RApport and our mission and goals.
The difference between medical debt and "moon debt"
The difference between investing in space exploration and investing in the biotech industry is about who bears the cost: society as a whole or people as individuals.
If Trikafta isn’t good enough for ICER, what drug Is?
ICER released a report concluding that Vertex’s groundbreaking triple-combination cystic fibrosis (CF) drug, Trikafta, is too expensive for the value it provides to patients. But is it?
Covid-19 teaches us the real definition of a 'novel drug'
Whatever therapy or intervention solves a previously unmet need is inherently novel. So any treatments for COVID-19 that turn out to work will be "novel" in every way that matters.